
The Abbott NMP22 BladderChek is a rapid, non-invasive urine test for the supportive detection and monitoring of bladder cancer. The test serves as a complementary tool to established diagnostic procedures and can be performed directly at the point of care.
Application areas
– Supportive diagnostics in cases of suspected bladder cancer
– Monitoring of disease progression and relapse in known diseases
– Use in high-risk patients according to medical assessment
– Application in doctors' offices, clinics and urological facilities
– Use as a supplement to conventional diagnostic methods such as cystoscopy or urine cytology
Advantages at a glance
– Non-invasive rapid test based on a urine sample
– Detection of a nuclear matrix protein (NMP22) released by urothelial tumor cells
– Results available within approximately 30 minutes
– Can be performed directly at the point of care
– Easy handling without complex laboratory equipment
– Suitable for supplementary assessment within the overall diagnostic picture
Further information
The NMP22 BladderChek test is designed as an adjunct to diagnostic testing and does not replace a medical diagnosis. According to published studies, the test has a sensitivity of over 82%, with values as high as 94% reported depending on the tumor stage. The reported specificity is approximately 76%. Studies suggest that sensitivity can be further increased when combined with urine cytology. Test results should always be interpreted in conjunction with clinical findings and other diagnostic procedures.
Manufacturer:
ABBOTT MEDICAL GMBH
Schanzenfeldstraße 2
D–35578 Wetzlar
Deutschland
Tel: +49 (0) 6441 870 75 0
Email: WETCustomerService@av.abbott.com
VAT ID number:
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Delivery information:
WEEE number:
Assistive device number: